Online Program Home
My Program

Abstract Details

Activity Number: 248 - Statistical Issues Specific the Therapeutic Areas- 2
Type: Contributed
Date/Time: Monday, July 30, 2018 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #329570 Presentation
Title: Innovative Approaches to Deal with Delayed Treatment Effect, Cure Fraction and Treatment Switching in Time-To-Event Data in Cancer Immuno-Therapies
Author(s): Carl Di Casoli* and Alessandro Previtali and Jonathan Jaeger and Marie-Laure Casaebaig
Companies: Halozyme Therapeutics and Celgene and Celgene and Celgene
Keywords: delayed treatment effect; Bayesian ; cancer immuno-therapies; proportional hazards; cure fraction; treatment switching

Delayed treatment effect (DTE), cure fraction (CF) and treatment switching (TS) are known to cause the violation of the proportional hazards assumption required in standard analyses of time-to-event data. We investigated their effect on power under different simulation conditions for various data distributions, durations of the study, accrual periods and analysis methods. Simulations show that power decreases dramatically in the presence of DTE and TS, whereas overpowered situations occur when CF is encountered in the experimental group. Underpowered situations occur when CF is experienced in both experimental and control groups. When DTE, CF and/or TS are considered at the design stage and integrated into the sample size calculation, an adjustment in the number of subjects may be required to maintain the targeted power. In conclusion, omitting DTE, CF and/or TS at the design stage could lead to drastic implications on power and impact the chance to appropriately identify a potential treatment effect. The implementation of Bayesian methods during the design stage is recommended in order to proactively anticipate the effect of DTE, CF and/or TS, allowing for a more efficient design.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program